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Introduction
Biobanks of  archival samples, including pathologic and forensic 
medical tissues, are needed to analyze the genetic and environ-
mental factors that contribute to human disease. Unlike experi-
mental studies using animal resources, human resources are not 
precisely controllable during sampling, and human genetics re-
quires mega-scale samples because of  genetic polymorphisms. In 
addition, for personalized medicine, the repeated and long-term 
use of  samples are inevitable, and the frequent follow-up of  the 
donors or participants concerning their health condition, occupa-
tion, and lifestyle (including eating habits) for epigenetic analysis 
would be inconvenient [1-6]. 
In Japan, the Tohoku Medical Megabank Organization (http://
www.megabank.tohoku.ac.jp/) and the BioBank Japan Project 
of  Tokyo University (src.riken.jp/english/project/person/) on 
the implementation of  personalized medicine are government-
supported large-scale biobanks, and six national medical institutes 
have been urged to collect millions of  specimens for statistical 
analysis of  genetic-based studies. The growth of  this collection 
will be accelerated by the Japan Agency for Medical Research and 
Development (AMED), which was established in 2015 April. In 
the present study, we review traditional informed consent (IC) 
formats in the context of  Japanese regulation of  human research. 
In actuality, the approach of  specified consent presents a sub-
stantial challenge. Preceding the discussion of  IC, we describe the 
main research regulations concerning the use of  human biospeci-
mens and clarify their uniqueness in a global context.
History of  Japanese Ethical Guidelines for Use of  
Human Resources
Japanese clinical research programs are reviewed by Institutional 
Review Boards (IRBs) (http://www.mhlw.go.jp/english/), in-
stalled according to guidelines of  the Japanese Ministry of  Ed-
ucation, Culture, Sports, Science and Technology (MEXT), the 
Japanese Ministry of  Health, Labor and Welfare (MHLW), and 
the Japanese Ministry of  Economy, Trade and Industry (METI) 
(http://www.lifescience.mext.go.jp/files/pdf/n1500_01.pdf).
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Japanese guidelines for medical research are classified into four 
types. Professional medical or academic groups have developed 
the first type. The second type results from the council or com-
mittee deliberations of  government agencies and is subsequently 
announced by the relevant ministries to agencies. The third ema-
nates from government agencies in the form of  a notification. 
The fourth is a guide according to legislation. Except for the last 
type, there is no concrete law enforcing the guidelines. Good 
Clinical Practice (GCP) for Trials on Drugs [Notification] was is-
sued by the Director of  the Pharmaceutical Affairs Bureau, and 
subsequently by the Ministry of  Health and Welfare [old GCP] 
in 1989. Regulation of  research on human subjects began in the 
1980s. Particularly, in 1990, the world's first gene therapy was con-
ducted in the US and the need for gene therapy legislation in Ja-
pan was recognized. At that time, recombinant DNA technology 
had advanced and the clinical use of  innovative gene therapies 
was expected to become widespread. For this reason, Guidelines 
Concerning Gene Therapy Clinical Research in Universities and 
Other Research Institutions [then the Ministry of  Education, Sci-
ence and Culture Notification No.79, 1994] and Guidelines for 
Gene Therapy Clinical Research were established in 1994. Based 
on these guidelines, the first gene therapy was performed in Japan 
in 1995 [7].
In 2000, the Japanese government planned the “Millennium Pro-
ject”, which aspired to create technical innovations that would 
produce new industries to solve many of  the problems faced by 
humans [8]. This included research into the prevention of  dis-
eases by gene analysis and drug discovery. Because the prediction 
of  familial disease was possible by genetic analysis, a novel ethical 
problem arose that had not been previously addressed. Regretful-
ly, in the 1990s, several gene analysis studies were conducted with-
out IC. In the wake of  these incidents, the Prime Minister's Office 
announced Fundamental Principles of  Research on the Human 
Genome. Additionally, Guidelines for Bioethical Problems Asso-
ciated with Genetic Analysis Research (the so-called "Millennium 
Guidelines") were formulated by the then Ministry of  Health and 
Welfare. In the same year, Bioethics Committee, Council for Sci-
ence and Technology Japan presented the basic principles: IC on 
the basis of  free-will, the right not to know, the right to know, the 
prohibition of  discrimination by genetic analysis, prior review of  
research programs by ethical review committees, and return of  
research results to society. These principles became the basis of  
Ethical Guidelines for Human Genome/Gene Analysis Research. 
However, by the end of  the 1990s, the government had still not 
regulated epidemiological studies using human bioresources be-
cause of  the minimal invasiveness during sampling. However, 
guidelines were created for these studies in the 2000s. Thus, basic 
ethical guidelines have been developed corresponding to research 
categories (clinical medical research, epidemiologic research, ge-
nome research and other studies) according to the degree of  risk 
to humans during sampling and to the sensitivity of  genome data 
information. This categorization remains a feature of  Japanese 
guidelines. Guidelines included obligations of  researchers and ob-
ligations of  research institutions, such as the installation of  IRBs.
Ethical Guidelines for Human Genome/Gene Analysis Re-
search
These guidelines were introduced in 2001 as guidelines for gen-
eral human genome and genetic analysis research (http://www.
lifescience.mext.go.jp/files/pdf/n796_00.pdf, 2008). Compliance 
with the guidelines is a condition for research project assistance, 
such as funding support from the relevant ministries and agencies. 
The guidelines are mainly concerned with personal information 
protection, ethical board review procedures, anonymity proce-
dures, and adequate procedures for obtaining IC, or limits to the 
donation of  bioresources to third parties. Because it is possible 
to extract personal information from human samples by genome 
analysis, the guidelines focus on the protection of  the most sensi-
tive of  the genomic information.
Ethical Guidelines for Epidemiological Research
In 2002, these guidelines were formulated according to the con-
clusions of  the Joint Committee of  MEXT and MHLW (http://
www.lifescience.mext.go.jp/files/pdf/n796_01.pdf). The guide-
lines were developed for application to large cohort epidemio-
logical studies, in which invasive samples are not collected from 
subjects. Compliance with the guidelines is a necessary condition 
for funding support. Additionally, compliance with the guidelines 
is required for other non-ministry-funded research undertaken. 
The guidelines define the responsibilities of  the president of  the 
research institute, the obligations of  researchers, and the estab-
lishment of  an IRB. The guidelines were amended several times 
and were most recently reviewed and amended by the relevant 
ministries in December 2013.
Ethical Guidelines for Clinical Studies
These guidelines were formulated in 2003 to be applied to all par-
ties who engage in clinical research [9]. At this time, the progress 
of  analytical technology enabled clinical research to rapidly ex-
pand. To control this situation, the guidelines encompassed the 
respect, dignity and human rights of  individuals. In March 2014, 
the Science Council of  Japan provided a recommendation regard-
ing the necessity for researchers to obey the regulations. In Japan, 
the government made a unique definition of  clinical trial stud-
ies whose purpose is to obtain new drug approval; this is distin-
guished from general clinical research, which is independent of  
the drug approval. This distinction is internationally unique. Up 
to this time, while trials had been regulated by quasi-legal Good 
Clinical Practices rules, laws underlying the regulation do not exist 
for independent clinical study. Compliance with the guidelines is a 
condition for support from the ministries, and those who violate 
the guidelines are subject to penalties. At the same time, compli-
ance with the guidelines was announced for all the research insti-
tutions in Japan, with corrective measures against any potential 
violator announced. The Personal Information Protection Law 
was also endorsed in the same year and other guidelines have been 
amended to match this law. From the view point of  guarantees 
of  freedom to research, academic research is not the subject of  
Act on the Protection of  Personal Information Held by Admin-
istrative Organs or the Independent Administrative Institutions 
Act on the Protection of  Personal Information (http://www.cas.
go.jp/jp/seisaku/hourei/data/APPIHAO.pdf); however, aca-
demic institutions are obligated to be compliant with these acts in 
the handling of  personal information.
Integration into Ethical Guidelines for Human Subjects Re-
search
Under the current Japanese regulations, ensuring research qual-
ity, including the prevention of  research misconduct, is regarded 
as highly important along with the protection of  subjects. The 
epidemiological guidelines and the clinical research guidelines underwent 




revision, and were concurrently integrated into Ethical Guidelines 
for Human Subjects Research (2014). The revision includes pro-
visions relating to monitoring and auditing, the conservation of  
research materials, and provisions relating to conflict of  interest.
As mentioned above, the majority of  research using human bi-
oresources has been conducted according to guidelines without 
a legal basis, whereas research that includes handling embryos or 
the violation of  human dignity has been regulated by law. Fur-
thermore, establishment of  human ES cells resulting in the loss 
of  fertilized eggs is strictly regulated by a Ministry process. Thus, 
three stages of  control have been implemented in Japan.
Discussion
To date, the Japanese Society of  Pathology has been formulating 
guidelines for the sampling and storage of  bioresources and man-
agement of  FFPE for research use. As mentioned, the absence 
of  a general guideline regulating storage and availability of  biore-
sources has been an institutional barrier against the conduct of  
clinical research using pathologic specimens in Japan. Individual 
research institutes autonomously conduct clinical research by IC, 
dispose of  sample waste, and take measures against infectious 
diseases with reference to Notification No. 1314 of  the Pharma-
ceutical and Food Safety Bureau (2012), according to approval of  
their IRB (http://www.jpma.or.jp/english/parj/pdf/2012.pdf). 
Thus, although IRBs are expected to provide advice, they have 
not been sufficiently qualified by an enactment, such as the Na-
tional Research Act in the US, since before 2004. For this reason, 
researchers assume the responsibility for planning their project 
while referring to Ministry guidelines, but clauses are complicated 
and often difficult to understand in Japan.
Many FFPEs are stored as archival samples in individual institu-
tional repositories for long periods of  time; however, the avail-
ability has been limited to analytical use.
First, the use of  FFPE specimens has been greatly changed by 
the development of  analytical methodologies, such as extraction 
of  DNA, RNA, and protein. We have previously reported on the 
proteomic usability of  cardiac [10] and colonic FFPE specimens 
[11, 12]. On the other hand, there are many kits for extracting 
DNA or RNA that produce RNA integrity numbers greater than 
8.0. (www.qiagen.com). The notable improvement of  extraction 
kits is a significant development that may trigger a serious issue 
in using FFPE specimens, because of  the possible use of  DNA 
sequences to identify donors. Therefore, more attention should 
be paid to the use of  FFPE.
Second, there is an ethical issue on the management of  IC. Our 
institute has studied IC for the use of  FFPE since 2005 (http://
www.ec.med.kyoto-u.ac.jp/). In principle, we cannot use archival 
FFPE from deceased donors if  the acquisition of  IC is strictly re-
quired for research use. To solve the issue of  archival FFPE use in 
research, we are required to make an effort to communicate with 
the donor's relatives [13]. In regards to the difficulties in commu-
nication, it was recently reported that the overwhelming majority 
of  families who are suddenly bereaved are willing to authorize 
research use of  tissue taken at the time of  postmortem examina-
tion [14]; the majority of  families authorized retention of  tissue 
samples for research and one-sixth agreed to whole tissue dona-
tion. According to this report, we are potentially allowed to use 
the tissue for use of  archived FFPE, if  we follow adequate ethi-
cal procedures. Therefore, we are preparing a webpage through 
which we will make archival FFPE broadly available for research 
use for a specified term. This notification is one of  the opt-out 
means and we will make archival FFPE available when their use 
is not definitely refused by donors and their relations during the 
notification term. Of  course, there are extensive discussions on 
the nature and length of  the notification period. It is likely that a 
one-year period is necessary for notification according to the civil 
laws in Japan.
Dynamic Consent is one of  the recently proposed forms in re-
sponse to the development of  information technology (IT), 
which makes contacting donors easy. Owing to these technical 
issues, many donors are prepared to consent broadly to future 
research use without frequent contact with researchers. This is an 
interesting method, but donors do not necessarily favor continu-
ous contact [15].
Recently, significant developments in the usability of  FFPE have 
had bioethical repercussions, and researchers are now faced with 
novel bioethics issues. However, we believe that IT technology 
will enable progress on such issues.
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